• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

给新生儿补充维生素K:影响与建议。

Administration of Vitamin K to newborns: implications and recommendations.

作者信息

McMillan D D

出版信息

CMAJ. 1996 Feb 1;154(3):347-9.

PMID:8564904
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1487525/
Abstract

The review by Drs. Brousson and Klein (see pages 307 to 315 of this issue) identifies controversies surrounding the administration of vitamin K to babies shortly after birth. Controlled studies comparing the effect of oral and intramuscular administration are unlikely to be conducted because of the large number of subjects needed. The evidence presented in the review should dispel concerns that intramuscular administration may be associated with childhood cancer. Oral administration of a single dose of vitamin K soon after is associated with significant biochemical vitamin K deficiency by 1 month of age, but the relation of biochemical abnormality to clinical manifestations of late hemorrhagic disease of the newborn is less clear. Epidemiologic studies indicate a small, but significant, increase in the incidence rate of hemorrhagic disease after oral administration of vitamin K (1.0 to 6.4 incidents per 1000 000 infants), compared with the incidence rate after intramuscular administration (0.25 incidents per 100 000 infants). Although repeated oral doses of vitamin K may be and effective alternative regimen, there is no approved oral vitamin K formulation, there are concerns about patient compliance, and there has been limited investigation of such regimen. Therefore, intramuscular administration of a single dose of 1.0 mg of vitamin K shortly after birth is recommended.

摘要

布鲁松博士和克莱因博士的综述(见本期第307至315页)指出了出生后不久给婴儿服用维生素K所存在的争议。由于所需受试者数量众多,不太可能开展比较口服和肌肉注射效果的对照研究。该综述中所呈现的证据应能消除人们对于肌肉注射可能与儿童癌症有关的担忧。出生后不久口服单剂量维生素K,到1月龄时会出现明显的生化性维生素K缺乏,但生化异常与新生儿晚期出血性疾病临床表现之间的关系尚不清楚。流行病学研究表明,与肌肉注射后的发病率(每10万名婴儿中有0.25例)相比,口服维生素K后出血性疾病的发病率有小幅但显著的上升(每100万名婴儿中有1.0至6.4例)。尽管重复口服维生素K可能是一种有效的替代方案,但目前尚无获批的口服维生素K制剂,存在患者依从性方面的担忧,且对此类方案的研究有限。因此,建议在出生后不久肌肉注射单剂量1.0毫克的维生素K。

相似文献

1
Administration of Vitamin K to newborns: implications and recommendations.给新生儿补充维生素K:影响与建议。
CMAJ. 1996 Feb 1;154(3):347-9.
2
Controversies surrounding the administration of vitamin K to newborns: a review.新生儿维生素K给药的争议:综述
CMAJ. 1996 Feb 1;154(3):307-15.
3
Prevention of vitamin K deficiency bleeding in breastfed infants: lessons from the Dutch and Danish biliary atresia registries.母乳喂养婴儿维生素K缺乏性出血的预防:来自荷兰和丹麦胆道闭锁登记处的经验教训。
Pediatrics. 2008 Apr;121(4):e857-63. doi: 10.1542/peds.2007-1788.
4
Vitamin K administration in neonates: survey of compliance with recommended practices in the Dunedin area.新生儿维生素K的使用:达尼丁地区推荐做法的依从性调查。
N Z Med J. 1995 Aug 25;108(1006):337-9.
5
Comparative study of oral versus injectable vitamin K in neonates.新生儿口服与注射维生素K的对比研究。
Indian Pediatr. 1992 Jul;29(7):857-9.
6
Effect of oral water soluble vitamin K on PIVKA-II levels in newborns.口服水溶性维生素K对新生儿异常凝血酶原-II水平的影响。
Indian Pediatr. 1995 Aug;32(8):863-7.
7
Vitamin K prophylaxis in the neonate by the oral route and its significance in reducing infant mortality and morbidity.新生儿口服维生素K预防及其在降低婴儿死亡率和发病率方面的意义。
J Med Assoc Thai. 1986 Oct;69 Suppl 2:56-61.
8
[Effect of oral and intramuscular vitamin K on the factors II, VII, IX, X, and PIVKA II in the infant newborn under 60 days of age].[口服和肌内注射维生素K对60日龄以内新生儿的凝血因子II、VII、IX、X及异常凝血酶原II的影响]
Rev Med Chil. 2001 Oct;129(10):1121-9.
9
Should intramuscular vitamin K prophylaxis for haemorrhagic disease of the newborn be continued? A decision analysis.新生儿出血性疾病的肌内维生素K预防措施是否应继续?一项决策分析。
N Z Med J. 1989 Jan 25;102(860):3-5.
10
Vitamin K and childhood cancer.维生素K与儿童癌症
N Z Med J. 1993 Dec 8;106(969):527-8.

引用本文的文献

1
An analysis of vitamin K status in Chinese healthy children aged 0-18 years.中国 0-18 岁健康儿童的维生素 K 状况分析。
BMC Pediatr. 2024 Nov 6;24(1):703. doi: 10.1186/s12887-024-05195-y.
2
Case report: fatal hemorrhagic disease in a newborn despite vitamin K prophylaxis.病例报告:尽管进行了维生素K预防,新生儿仍患致命性出血性疾病。
Can Fam Physician. 1998 Sep;44:1893-4, 1896.

本文引用的文献

1
Epidemiology of late onset haemorrhagic disease: a pooled data analysis.迟发性出血性疾病的流行病学:一项汇总数据分析
J Paediatr Child Health. 1993 Jun;29(3):177-81. doi: 10.1111/j.1440-1754.1993.tb00480.x.
2
Vitamin K1 concentration in breast-fed neonates after oral or intramuscular administration of a single dose of a new mixed-micellar preparation of phylloquinone.口服或肌肉注射单剂量新型叶绿醌混合微乳制剂后母乳喂养新生儿的维生素K1浓度
J Pediatr Gastroenterol Nutr. 1993 May;16(4):435-9. doi: 10.1097/00005176-199305000-00016.
3
Compliance with recommendations for giving vitamin K to newborn infants.新生儿维生素K给药建议的依从性。
BMJ. 1994 Apr 2;308(6933):894-5. doi: 10.1136/bmj.308.6933.894.
4
Effect of neonatal circumcision on pain responses during vaccination in boys.新生儿包皮环切术对男孩接种疫苗时疼痛反应的影响。
Lancet. 1995 Feb 4;345(8945):291-2. doi: 10.1016/s0140-6736(95)90278-3.
5
Vitamin K in infancy.婴儿期的维生素K
J Pediatr. 1985 Mar;106(3):351-9. doi: 10.1016/s0022-3476(85)80656-9.
6
Acarboxyprothrombin concentration [corrected] after oral prophylactic vitamin K.口服预防性维生素K后[校正的]血清凝血酶原浓度
Arch Dis Child. 1987 Sep;62(9):938-40. doi: 10.1136/adc.62.9.938.
7
Vitamin K in infancy.婴儿期的维生素K
Eur J Pediatr. 1988 Feb;147(2):106-12. doi: 10.1007/BF00442204.
8
Factors associated with childhood cancer in a national cohort study.一项全国队列研究中与儿童癌症相关的因素。
Br J Cancer. 1990 Aug;62(2):304-8. doi: 10.1038/bjc.1990.283.
9
Comparison of oral and parenteral vitamin K prophylaxis for prevention of late hemorrhagic disease of the newborn.口服与肠外维生素K预防新生儿晚期出血性疾病的比较。
J Pediatr. 1991 Sep;119(3):461-4. doi: 10.1016/s0022-3476(05)82064-5.
10
Late haemorrhagic disease in Sweden 1987-89.1987 - 1989年瑞典的晚发性出血性疾病
Acta Paediatr Scand. 1991 Oct;80(10):966-8. doi: 10.1111/j.1651-2227.1991.tb11763.x.